TC Biopharm (Holdings) Plc (NASDAQ: TCBP) stock jumped 9.47% on Monday to $0.52 against a previous-day closing price of $0.47. With 1.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 91700.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5900 whereas the lowest price it dropped to was $0.4900. The 52-week range on TCBP shows that it touched its highest point at $96.10 and its lowest point at $0.36 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at -0.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TCBP was up-trending over the past week, with a rise of 27.14%, but this was down by -85.95% over a month. Three-month performance dropped to -89.70% while six-month performance fell -93.59%. The stock lost -99.42% in the past year, while it has lost -98.65% so far this year.
Float and Shares Shorts:
At present, 0.35 million TCBP shares are outstanding with a float of 0.22 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.16 million, which was 1.75% higher than short shares on Sep 28, 2023. In addition to Mr. Bryan L. Kobel as the firm’s CEO & Director, Mr. Martin E. Thorp serves as its CFO & Director.
Through their ownership of 5.23% of TCBP’s outstanding shares, institutional investors have minority control over the company. As the largest shareholder in TCBP with 19.01% of the stake, Modera Wealth Management LLC holds 1,083,793 shares worth 1,083,793. A second-largest stockholder of TCBP, Armistice Capital LLC, holds 297,500 shares, controlling over 5.22% of the firm’s shares. Csenge Advisory Group LLC is the third largest shareholder in TCBP, holding 26,000 shares or 0.46% stake.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TCBP since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With TCBP analysts setting a high price target of $5.61 and a low target of $5.61, the average target price over the next 12 months is $5.61. Based on these targets, TCBP could surge 978.85% to reach the target high and rise by 978.85% to reach the target low. Reaching the average price target will result in a growth of 978.85% from current levels.